Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S177-S180 , March 2004

Ten years of cyclosporine use in renal transplantation: a single-center experience with 479 renal transplants

  • M Lucan

      Affiliations

    • Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania.
    • Corresponding Author InformationAddress reprint requests to M. Lucan, Clinical Institute of Urology and Renal Transplantation, 4-6 Clinicilor Str., 400006 Cluj-Napoca, Romania.
    • ,
  • G Iacob

      Affiliations

    • Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania.
    • ,
  • C Lucan

      Affiliations

    • Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania.
    • ,
  • C Lăpuşan

      Affiliations

    • Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania.
    • ,
  • A Munteanu

      Affiliations

    • Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania.
    • ,
  • S Sîrbu

      Affiliations

    • Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania.

References 

  1. Schwartz R, Dameshek W. Drug-induced immunologic tolerance. Nature. 1959;183:1682
  2. Murray JE, Merrill JP, Harrison JH, et al.  Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963;268:1315
  3. The EBPG Expert Group on Renal Transplantation . Initial and maintenance immunosuppressive treatment. Nephrol Dial Transplant. 2000;15(suppl 7):64
  4. Myers BD, Ross J, Newton L, et al.  Cyclosporin-associated chronic nephropathy. N Engl J Med. 1984;311:699
  5. Clipstone NA, Crabtree GR. Calcineurin is the key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drug. Ann NY Acad Sci USA. 1993;696:20
  6. Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. QJM. 2000;93:15
  7. Ojo AO, Meier-Kriesche H-U, Hanson JA, et al.  Mycophenolate mofetil reduces late allograft loss independent of acute rejection. Transplantation. 2000;69:2405
  8. Cole E, Maham N, Cardella C, et al.  Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation. 2003;72:2086
  9. Sehgal SN, Molnar-Kimbar K, Ocain TD, et al.  Rapamycin. A novel immunosuppressive macrolide. Med Res Rev. 1994;14:1
  10. Andoh TF, Burdmann EA, Fransechini N, et al.  Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int. 1996;50:1110
  11. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus (a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients). Kidney Int. 1996;49:209
  12. Kahan BD, Camardo JS. Rapamycin (clinical results and future opportunities). Transplantation. 2001;72:1181
  13. Backman L, Morales JM. Is non-nephrotoxic immunosuppression a possibility?. Transplantation. 2000;69:SS27
  14. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation (a review of the evidence). Kidney Int. 2001;59:3

PII: S0041-1345(03)01336-8

doi: 10.1016/j.transproceed.2003.12.025

Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S177-S180 , March 2004

Article Tools

* Image Usage & Resolution